Advicenne News Today

AMSTERDAM, October 18, 2023--Avanzanite's expanded collaboration with Advicenne now includes Ireland, Cyprus and Malta in addition to existing markets (DE, AT, CH, GR, LI).

Regulatory News: Advicenne(Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering

Advicenne announces the approval of all resolutions supported by the Board of Directors at its Combined General Meeting Paris , June 9, 2023 - 8.00 am CET - The... | June 9, 2023

Availability of preparatory documents Regulatory News: Advicenne (Euronext Growth Paris ALDVI FR0013296746)(Paris:ALDVI), a specialty pharmaceutical company dedicated to the development and commercialization

Sibnayal (potassium citrate/potassium bicarbonate) has been launched on March 1, 2023 Reference price equals to an annual treatment cost of €15,000 per patient. Regulatory News: Advicenne

Advicenne agreement further validates Avanzanite's unique business model and establishes it as the go-to commercialization partner for medicines treating rare diseases across Europe Avanzanite

Sibnayal® will now be available in four of the five major European markets Significant expansion of commercial opportunities for Sibnayal® (potassium citrate/ potassium bicarbonate) Regulatory

Significant progress in the operational deployment of partnerships to support Sibnayal® commercial roll-out Sustained growth in the number of patients with access to Sibnayal® in Europe Regulatory

Significant progress in the operational deployment of partnerships to support Sibnayal® commercial roll-out Sustained growth in the number of patients with access to Sibnayal® in Europe Regulatory

Sales of Sibnayal® reached 1.4 million euros, a significant increase of 40% over one year Significant growth acceleration in H2 2022 Regulatory News: Advicenne (Euronext: ADVIC), a specialty